Home/Pipeline/ZYNPN

ZYNPN

Neuropathic Pain

Pre-clinicalActive

Key Facts

Indication

Neuropathic Pain

Phase

Pre-clinical

Status

Active

Company

Zyneyro

About Zyneyro

Zyneyro is a preclinical-stage biotech developing first-in-class peptide therapeutics for chronic pain by targeting the protein PICK1, a novel mechanism identified through foundational academic research. The company's lead candidate, ZYNPN, has demonstrated efficacy in multiple preclinical pain models without impairing normal pain perception or cognitive function, positioning it as a potential non-opioid alternative. Founded by University of Copenhagen neuroscientists and backed by a strong scientific advisory board, Zyneyro is advancing towards first-in-human studies. The company operates as a private, pre-revenue entity targeting the large and underserved neuropathic pain market.

View full company profile

Therapeutic Areas

Neuropathic Pain Chronic Pain

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
Peripheral nerve pain agent	Nyrada	Preclinical	Active
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
LAT9997	Lateral Pharma	Phase 2 (next-gen)	Active; composition-of-matter patent secured
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
ONO-2910	Ono Pharmaceutical	Phase 2	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
BDT272	KYORIN Pharmaceutical	Preclinical	Active (In-licensed)
HSK16149	Haisco Pharmaceutical Group	Phase III	Active